1. Home
  2. RYTM vs OMAB Comparison

RYTM vs OMAB Comparison

Compare RYTM & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$82.62

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

OMAB

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

HOLD

Current Price

$104.85

Market Cap

5.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
OMAB
Founded
2008
1998
Country
United States
Mexico
Employees
N/A
1326
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.7B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
RYTM
OMAB
Price
$82.62
$104.85
Analyst Decision
Strong Buy
Buy
Analyst Count
14
4
Target Price
$131.14
$120.00
AVG Volume (30 Days)
505.0K
74.4K
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
4.06%
EPS Growth
28.34
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.34
$8.36
Revenue Next Year
$86.06
$13.05
P/E Ratio
N/A
$21.86
Revenue Growth
N/A
N/A
52 Week Low
$55.31
$86.62
52 Week High
$122.20
$134.99

Technical Indicators

Market Signals
Indicator
RYTM
OMAB
Relative Strength Index (RSI) 39.88 35.69
Support Level $74.50 $104.37
Resistance Level $90.79 $109.14
Average True Range (ATR) 3.24 3.42
MACD -0.28 -1.11
Stochastic Oscillator 23.60 9.43

Price Performance

Historical Comparison
RYTM
OMAB

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.

Share on Social Networks: